Shares of Affimed (NASDAQ: AFMD) have been soaring on the back of positive clinical trial results for an experimental cancer therapy that could be worth billions. The stock has already gained around 61% this year, but some biotech investors think it could climb much higher.
Can Affimed really make a millionaire out of the average investor? To find out, we'll need to look at what's driven the stock to recent peaks and what still needs to happen before it can make you rich.
Image source: Getty Images.
For further details see:
Could Affimed Be a Millionaire-Maker Stock?